SCHEMBL946441

SCHEMBL946441

COc1ccc(S(=O)(=O)n2cc(C(C)=O)c3ccccc32)cc1

nearest known ligand 0.76

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.76
SMN1; SMN2 Q16637 1/20 0.76
MEN1 O00255 1/20 0.63
KMT2A Q03164 1/20 0.63
HTR6 P50406 10/20 0.60
AKR1C3 P42330 1/20 0.57
AKR1C1 Q04828 1/20 0.57
PLK1 P53350 1/20 0.56
CA2 P00918 1/20 0.55
CA9 Q16790 1/20 0.55
ALOX5 P09917 2/20 0.53
PPARG P37231 1/20 0.51
PPARD Q03181 1/20 0.51
PPARA Q07869 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL949506 0.90 AKR1C3 (0.72) LMNASMN1; SMN2MEN1KMT2AHTR6
SCHEMBL30393652 0.86 LMNA (1.00) LMNASMN1; SMN2MEN1KMT2AHTR6
SCHEMBL949716 0.86 LMNA (1.00) LMNASMN1; SMN2MEN1KMT2AHTR6
SCHEMBL949348 0.85 LMNA (0.82) LMNASMN1; SMN2MEN1KMT2AHTR6
SCHEMBL30394720 0.85 LMNA (0.68) LMNASMN1; SMN2MEN1KMT2AHTR6
SCHEMBL31202601 0.82 LMNA (0.76) LMNASMN1; SMN2MEN1KMT2AHTR6
SCHEMBL946881 0.82 LMNA (0.76) LMNASMN1; SMN2MEN1KMT2AHTR6
SCHEMBL948004 0.81 HTR6 (0.54) LMNASMN1; SMN2MEN1KMT2AHTR6
SCHEMBL948005 0.81 TNF (0.69) LMNASMN1; SMN2MEN1KMT2AHTR6
SCHEMBL945681 0.81 HTR6 (0.76) HTR6PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875605-B2 1-Benzenesulfonyl-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole; 1-[[5-Bromo-1-(2-Bromo-4-methoxybenzenesulfonyl)-indo1-3-yl]methyl][1,4]diazepane; useful for treating psychotic and neurodegenerative disorders e.g. schizophrenia, Alzheimer's disease, Parkinson's disease and Huntington's chorea SUVEN LIFE SCIENCES LIMITED (IN) 2011-01-25 US disclosed
EP-1581492-B1 N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM SUVEN LIFE SCIENCES LTD (IN) 2008-07-16 EP disclosed
US-20060223890-A1 N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them SUVEN LIFE SCIENCES LIMITED (IN) 2006-10-05 US disclosed
EP-1581492-A1 N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM Suven Life Sciences Limited (IN) 2005-10-05 EP disclosed
WO-2004048330-A1 N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM SUVEN LIFE SCIENCES LIMITED (IN) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223890-A1 N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them HTR3A, HTR3C, HTR2C LMNA 2304/4885SMN1; SMN2 2056/4885MEN1 3756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.